The DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index.
Comparison of Combined Bupropion and Naltrexone Therapy for Obesity with Monotherapy and Placebo
Abstract
CONTEXT: The efficacy of current centrally acting obesity pharmacotherapies is limited by compensatory mechanisms that mitigate weight loss. OBJECTIVE: Our objective was to determine whether opioid receptor antagonism (naltrexone) plus pro-opiomelanocortin activation (bupropion) causes greater weight loss than placebo or monotherapy. DESIGN/SETTING: A randomized, placebo- and monotherapy-controlled, double-blind, dose-finding trial was conducted from August 2005 to December 2006 in seven U.S. outpatient clinics. PARTICIPANTS: A total of 419 patients with uncomplicated obesity participated. INTERVENTIONS: Interventions included 24 wk of sustained-release bupropion (400 mg/d), immediate-release naltrexone (48 mg/d), placebo, and three combination therapy [naltrexone/bupropion (NB)] groups consisting of immediate-release naltrexone, 16, 32, or 48 mg/d, plus sustained-release bupropion (400 mg/d) with a 24-wk extension. A minimal diet and exercise component was also included. MAIN OUTCOME MEASURES: Percent weight change from baseline at wk 24 in the intent-to-treat population for NB48 vs. placebo and monotherapy was assessed. Other measurements included body mass index, waist circumference, fasting lipids, glycemic variables, safety, and tolerability. RESULTS: At wk 24, placebo-subtracted weight loss was -4.62% [95% confidence interval (CI) -6.24 to -2.99; P < 0.001] for NB16, -4.65% (95% CI -6.20 to -3.09; P < 0.001) for NB32, and -3.53% (95% CI -5.15 to -1.90; P < 0.001) for NB48. Weight loss was statistically significant vs. monotherapy for all three NB combinations with the exception of NB48 vs. bupropion. Weight loss with NB continued after wk 24. The most common treatment-emergent adverse event was mild transient nausea. CONCLUSIONS: NB caused gradual sustained weight loss over 48 wk; NB32 and NB16 demonstrated greater weight loss in the intent-to-treat population due to lower attrition rates. Further study is needed to demonstrate long-term efficacy and safety of NB.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Secondary analyses show the benefits of binge frequency and global impressions of severity [139].”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [139]
Experimental — accuracy not yet measuredIn the citing paper
“Highly-effective AOMs, including nutrient-stimulated hormone-based therapies, induce mean weight loss of 15% or more.”
From Approach to Obesity Treatment in Primary Care: A Review (2024) · cites this paper as [68]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (1983) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1983.tb09716.x · Cited by 47,139
Excess Deaths Associated With Underweight, Overweight, and Obesity
Flegal, K. M. (2005) · JAMA · doi:10.1001/jama.293.15.1861 · Cited by 2,811
Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects
(2014) · Jahrbuch für Wissenschaft und Ethik · doi:10.1515/jwiet-2014-0117 · Cited by 2,483
Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus
Cowley, M. A., Smart, J. L., Rubinstein, M., Cerdán, M. G., Diano, S., Horvath, T. L., Cone, R. D., & Low, M. J. (2001) · Nature · doi:10.1038/35078085 · Cited by 2,356
Self-citationWang, G.-J., Volkow, N. D., Logan, J., Pappas, N. R., Wong, C. T., Zhu, W., Netusll, N., & Fowler, J. S. (2001) · The Lancet · doi:10.1016/s0140-6736(00)03643-6 · Cited by 1,864
Anatomy and regulation of the central melanocortin system
Cone, R. D. (2005) · Nature Neuroscience · doi:10.1038/nn1455 · Cited by 1,583
The Neuroscience of Natural Rewards: Relevance to Addictive Drugs
Kelley, A. E., & Berridge, K. C. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-09-03306.2002 · Cited by 1,505
Association between obesity and psychiatric disorders in the US adult population
Simon, G. E., Von Korff, M., Saunders, K., Miglioretti, D. L., Crane, P. K., van Belle, G., & Kessler, R. C. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.7.824 · Cited by 1,338
How can drug addiction help us understand obesity?
Volkow, N. D., & Wise, R. A. (2005) · Nature Neuroscience · doi:10.1038/nn1452 · Cited by 1,089
Mykletun, A., Stordal, E., & Dahl, A. A. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.179.6.540 · Cited by 908
Long term pharmacotherapy for obesity and overweight: updated meta-analysis
Rucker, D., Padwal, R., Li, S. K., Curioni, C., & Lau, D. C. W. (2007) · BMJ · doi:10.1136/bmj.39385.413113.25 · Cited by 801
Relation Between Obesity and Blunted Striatal Response to Food Is Moderated by Taq IA A1 Allele
Stice, E., Spoor, S., Bohon, C., & Small, D. M. (2008) · Science · doi:10.1126/science.1161550 · Cited by 786
Development and Validation of the Food‐Craving Inventory
White, M. A., Whisenhunt, B. L., Williamson, D. A., Greenway, F. L., & Netemeyer, R. G. (2002) · Obesity Research · doi:10.1038/oby.2002.17 · Cited by 471
Self-citationRational Design of a Combination Medication for the Treatment of Obesity
Greenway, F. L., Whitehouse, M. J., Guttadauria, M., Anderson, J. W., Atkinson, R. L., Fujioka, K., Gadde, K. M., Gupta, A., O'Neil, P. M., Schumacher, D., et al. (2008) · Obesity · doi:10.1038/oby.2008.461 · Cited by 347
Self-citationOpioid peptides and the control of human ingestive behaviour
Yeomans, M. R., & Gray, R. W. (2002) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(02)00041-6 · Cited by 317
Bupropion SR Enhances Weight Loss: A 48‐Week Double‐Blind, Placebo‐ Controlled Trial
Anderson, J. W., Greenway, F. L., Fujioka, K., Gadde, K. M., McKenney, J., & O'Neil, P. M. (2002) · Obesity Research · doi:10.1038/oby.2002.86 · Cited by 315
Self-citationThe prevention of type 2 diabetes
F. T. D. P. P. R. G., Crandall, J. P., Knowler, W. C., Kahn, S. E., Marrero, D., Florez, J. C., Bray, G. A., Haffner, S. M., Hoskin, M., & Nathan, D. M. (2008) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0843 · Cited by 261
Bupropion SR vs. Placebo for Weight Loss in Obese Patients with Depressive Symptoms
Jain, A. K., Kaplan, R. A., Gadde, K. M., Wadden, T. A., Allison, D. B., Brewer, E. R., Leadbetter, R. A., Richard, N., Haight, B., Jamerson, B. D., et al. (2002) · Obesity Research · doi:10.1038/oby.2002.142 · Cited by 205
Duration of occupancy of opiate receptors by naltrexone.
Lee, M. C., Wagner, H. N., Tanada, S., Frost, J. J., Bice, A. N., & Dannals, R. F. (1988) · PubMed · Cited by 189
Effects of long-term therapy with naltrexone on body weight in obesity
Atkinson, R. L., Berke, L., Drake, C. R., Bibbs, M. L., Williams, F. L., & Kaiser, D. L. (1985) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1985.197 · Cited by 163
Weight Change in Diabetes and Glycemic and Blood Pressure Control
Feldstein, A. C., Nichols, G. A., Smith, D. H., Stevens, V. J., Bachman, K. H., Rosales, A. G., & Perrin, N. (2008) · Diabetes Care · doi:10.2337/dc08-0426 · Cited by 142
High-dose naltrexone therapy and dietary counseling for obesity
Mitchell, J. E., Morley, J. E., Levine, A. S., Hatsukami, D., Gannon, M. C., & Pfohl, D. (1987) · Biological Psychiatry · doi:10.1016/0006-3223(87)90127-2 · Cited by 100
A controlled trial of naltrexone in obese humans.
Malcolm, R. J., O'Neil, P. M., Sexauer, J. D., Fe, R., Currey, H. S., & Counts, C. (1985) · PubMed · Cited by 97
Research works printed but not linked: 1
- 2001, The Surgeon General’s call to action to prevent and decrease overweight and obesity
Cited by
Sorted by citations
Long-term persistence of hormonal adaptations to weight loss
Sumithran, P., Prendergast, L. A., Delbridge, E., Purcell, K., Shulkes, A., Kriketos, A., & Proietto, J. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105816 · Cited by 1,449
Greenway, F. L., Fujioka, K., Plodkowski, R. A., Mudaliar, S., Guttadauria, M., Erickson, J., Kim, D. D., & Dunayevich, E. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60888-4 · Cited by 1,036
Self-citationApovian, C. M., Aronne, L., Rubino, D., Still, C., Wyatt, H., Burns, C., Kim, D., Dunayevich, E., & for the COR‐II Study Group (2013) · Obesity · doi:10.1002/oby.20309 · Cited by 720
Self-citationTirzepatide as Compared with Semaglutide for the Treatment of Obesity
Aronne, L. J., Horn, D. B., le Roux, C. W., Ho, W., Falcon, B. L., Gomez Valderas, E., Das, S., Lee, C. J., Glass, L. C., Senyucel, C., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2416394 · Cited by 634
Wadden, T. A., Foreyt, J. P., Foster, G. D., Hill, J. O., Klein, S., O'Neil, P. M., Perri, M. G., Pi‐Sunyer, F. X., Rock, C. L., Erickson, J. S., et al. (2011) · Obesity · doi:10.1038/oby.2010.147 · Cited by 558
Self-citation
Metadata
- Authors
- Greenway, F. L., Dunayevich, E., Tollefson, G., Erickson, J., Guttadauria, M., Fujioka, K., Cowley, M. A., & for the NB-201 Study Group
- Affiliations
- Pennington Biomedical Research Center (US)
- Orexigen Therapeutics (United States) (US)
- Indiana University School of Medicine (US)
- MG Consulting, Inc. (M.G.), New York, New York 10462
- Scripps Health (US)
- Corresponding author
- Greenway, Frank L.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2009-12-01
- Volume
- 94
- Issue
- 12
- Pages
- 4898-4906
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2036089668
- Cited by
- 179
- References
- 24
- Citations by year
- 2026: 4 · 2025: 12 · 2024: 7 · 2023: 4 · 2022: 5 · 2021: 9 · 2020: 11 · 2019: 10 · 2018: 8 · 2017: 9 · 2016: 13 · 2015: 17 · 2014: 12 · 2013: 14 · 2012: 10
- FWCI
- 10.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Louisiana State University
- Orexigen Therapeutics
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- obesity, bupropion, naltrexone, combination pharmacotherapy, weight loss, opioid antagonism, proopiomelanocortin, sustained weight loss, dose-finding, nausea, fasting lipids, glycemic control, waist circumference, body mass index, diet and exercise, treatment discontinuation, drug safety and tolerability
- MeSH terms
- Adolescent, Adult, Appetite, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Naltrexone, Narcotic Antagonists, Obesity, Risk Factors, Cohort Studies, Weight Loss, Bupropion, Dopamine Uptake Inhibitors, Endpoint Determination, Positron-Emission Tomography, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
